Taysha Gene TherapiesNASDAQ: TSHA

Taysha Gene Therapies (NASDAQ: TSHA ) stock is taking a beating on Wednesday after the gene therapy company announced a proposed public offering for its shares. Taysha Gene Therapies says that it intends to offer up to $75 million worth of TSHA stock in this offering.

DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) held its Q1 2024 Earnings Conference Call on May 14, 2024 at 4:30 PM ET. Key company representatives present included Hayleigh Collins, Sean Nolan, Sukumar Nagendran, and Kamran Alam. Various analysts and investors also participated in the call.

Taysha Gene Therapies, Inc. (TSHA) reported a quarterly loss of $0.10 per share, slightly better than the expected loss of $0.11 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.28 per share reported in the same quarter last year.

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

DALLAS, March 14, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the full-year ended December 31, 2023, provide corporate and clinical updates and host a corporate update conference call on Tuesday, March 19, 2024, at 4:30 PM Eastern Time.

Taysha Gene Therapies, Inc. (NASDAQ:TSHA ) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants Hayleigh Collins - Director and Head of Corporate Communications Sean Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of Research and Development Kamran Alam - Chief Financial Officer Conference Call Participants Whitney Ijem - Canaccord Genuity Kristen Kluska - Cantor Fitzgerald Salveen Richter - Goldman Sachs Gil Blum - Needham & Co Yanan Zhu - Wells Fargo Securities Jack Allen - Baird Joon Lee - Truist Securities Silvan Tuerkcan - JMP Securities Operator Good afternoon and welcome to the Taysha Gene Therapies Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

Taysha Gene Therapies is a biotech stock focused on developing gene therapies for monogenic CNS diseases, with its lead candidate TSHA-102 targeting Rett Syndrome. The gene therapy market is projected to grow from $15.46 billion in 2022 to $82.24 billion by 2032, highlighting a shift towards personalized medicine. TSHA-102 has received the FDA's Fast Track Designation, expediting its Phase 1/2 trial with a roadmap to treat the first pediatric patient by Q1 2024.

Taysha Gene Therapies, Inc. (TSHA) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, TSHA's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.